Role of Tachykinin 1 and 4 Gene-Derived Neuropeptides and the Neurokinin 1 Receptor in Adjuvant-Induced Chronic Arthritis of the Mouse

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Borbély, Éva ^a   Hajna, Zsófia ^a   Sándor, Katalin ^a   Kereskai, László ^a   Tóth, István ^a   Pintér, Erika ^a   Nagy, Péter ^a   Szolcsányi, János ^a   Quinn, John ^b   Zimmer, Andreas ^c   Stewart, James ^b   Paige, Christopher ^d,e   Berger, Alexandra ^d,e   Helyes, Zsuzsanna ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BONN   (Germany)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; NEUROKININ 1 RECEPTOR; TACHYKININ; TACHYKININ 1; TACHYKININ 4; UNCLASSIFIED DRUG; FREUND ADJUVANT; PROTEIN PRECURSOR; SUBSTANCE P; TAC4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; CHRONIC ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; GENE; GENE DELETION; GENE FUNCTION; HISTOPATHOLOGY; HYPERALGESIA; MOUSE; NONHUMAN; PAIN THRESHOLD; PATHOGENESIS; TAC1 GENE; TAC4 GENE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; EDEMA; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION REGULATION; GENETICS; HINDLIMB; INFLAMMATION; JOINT; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PLETHYSMOGRAPHY; SIGNAL TRANSDUCTION;

ANIMALIA; MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; EDEMA; FREUND'S ADJUVANT; GENE EXPRESSION REGULATION; HYPERALGESIA; INFLAMMATION; INTERLEUKIN-1BETA; JOINTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLETHYSMOGRAPHY; PROTEIN PRECURSORS; RECEPTORS, NEUROKININ-1; SIGNAL TRANSDUCTION; SUBSTANCE P; TACHYKININS; TARSUS, ANIMAL;

EID: 84876514896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061684     Document Type: Article

References (56)

1. Abdel-Nasser AM, Rasker JJ, Valkenburg HA, (1997) Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Seminars in Arthritis & Rheumatism 27: 123-140.
2. Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA, (1986) Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol 12: 406-11.
3. Schaible HG, von Banchet GS, Boettger MK, Bräuer R, Gajda M, et al. (2010) The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci. 1193: 60-9.
4. Maggi CA, (1995) Tachykinins and calcitonin gene-related peptide (CGRP) as cotransmitters released from peripheral endings of sensory nerves. Prog Neurobiol. 45: 1-98.
5. Szolcsanyi J, (1996) Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Prog Brain Res. 113: 343-59.
6. Anichini M, Cesaretti S, Lepori M, Maddali Bongi S, Maresca M, et al. (1997) Substance P in the serum of patients with rheumatoid arthritis. Rev Rhum Engl Ed. 64: 18-21.
7. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E, (1991) Concentration of substance P, neurokinin A, calcitonin generelated peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 20: 326-35.
8. Bileviciute I, Lundeberg T, Ekblom A, Theodorsson E, (1993) Bilateral changes of substance P-, neurokinin A-, calcitonin gene-related peptide- and neuropeptide Y-like immunoreactivity in rat knee joint synovial fluid during acute monoarthritis. Neurosci Lett 153: 37-40.
9. Stewart JP, Kipar A, Cox H, Payne C, Vasiliou S, et al. (2008) Induction of tachykinin production in airway epithelia in response to viral infection. PLoS ONE 3: e1673.
10. Millward-Sadler SJ, Mackenzie A, Wright MO, Lee HS, Elliot K, et al. (2003) Tachykinin expression in cartilage and function in human articular chondrocyte mechanotransduction. Arthritis Rheum 48: 146-156.
11. Howard MR, Millward-Sadler SJ, Vasilliou AS, Salter DM, Quinn JP, (2008) Mechanical stimulation induces preprotachykinin gene expression in osteoarthritic chondrocytes which is correlated with modulation of the transcription factor neuron restrictive silence factor. Neuropeptides 42: 681-686.
12. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ, (2000) Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 1: 392-397.
13. Duffy RA, Hedrick JA, Randolph G, Morgan CA, Cohen-Williams ME, et al. (2003) Centrally administered Hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology 45: 242-250.
14. Berger A, Paige CJ, (2005) Hemokinin-1 has substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J. Neuroimmunol 164: 48-56.
15. Kurtz MM, Wang R, Clements MK, Cascieri MA, Austin CP, et al. (2002) Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 296: 205-212.
16. Page NM, (2004) Hemokinins and endokinins. Cell Mol Life Sci. 61: 1652-63.
17. Page NM, (2006) Characterization of the gene structures, precursor processing and pharmacology of the endokinin peptides. Vascul Pharmacol 45: 200-208.
18. Endo D, Ikeda T, Ishida Y, Yoshioka D, Nishimori T, (2006) Effect of intrathecal administration of hemokinin-1 on the withdrawal response to noxious thermal stimulation of the rat hind paw. Neurosci Lett 392: 114-117.
19. Graham GJ, Stevens JM, Page NM, Grant AD, Brain SD, et al. (2004) Tachykinins regulate the function of platelets. Blood 104: 1058-1065.
20. Longmore J, Hill RG, Hargreaves RJ, (1997) Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol 75: 612-621.
21. Pernow B, (1983) Substance P - a putative mediator of antidromic vasodilation. Gen Pharmacol 14: 13-16.
22. Metwali A, Blum AM, Elliott DE, Setiawan T, Weinstock JV, (2004) Cutting edge: Hemokinin has substance P-like function and expression in inflammation. J Immunol 172: 6528-6532.
23. Nelson DA, Bost KL, (2004) Non-neuronal mammalian tachykinin expression. Front Biosci 9: 2166-2176.
24. Hill R, (2000) NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci. 7: 244-6.
25. Urban LA, Fox AJ, (2000) NK1 receptor antagonists-are they really without effect in the pain clinic? Trends Pharmacol Sci. 12: 462-4.
26. Zimmer A, Zimmer AM, Baffi J, Usdin T, Reynolds K, et al. (1998) Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci U S A. 3: 2630-5.
27. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, et al. (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 26: 394-7.
28. Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, et al. (2000) Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience. 98: 345-52.
29. Helyes Zs, Szabó Á, Németh J, Jakab B, Pintér E, et al. (2004) Anti-inflammatory and analgesic effect of somatostatin released from capsaicin-sensitive sensory nerve terminals in Freund's adjuvant-induced chronic arthritis model of the rat. Arthritis Rheum 50: 1677-85.
30. Berger A, Benveniste P, Corfe SA, Tran AH, Barbara M, et al. (2010) Targeted deletion of the tachykinin 4 gene (TAC4-/-) influences the early stages of B lymphocyte development. Blood 116: 3792-801.
31. Berger A, Tran AH, Dida J, Minkin S, Gerard NP, et al. (2012) Diminished pheromone-induced sexual behavior in neurokinin-1 receptor deficient (TACR1(-/-)) mice. Genes Brain Behav. 11: 568-76.
32. Szabó Á, Helyes Zs, Sándor K, Bite A, Pintér E, et al. (2005) Role of TRPV1 receptors in adjuvant-induced chronic arthritis: in vivo study using gene-deficient mice. J Pharmacol Exp Ther 314: 111-9.
33. Bölcskei K, Helyes Zs, Szabó Á, Sándor K, Petho G, et al. (2005) Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using genedeficient mice. Pain 117: 368-76.
34. Helyes Zs, Pintér E, Németh J, Sándor K, Elekes K, et al. (2006) Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 149: 405-15.
35. Bevaart L, Vervoordeldonk MJ, Tak PP, (2010) Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 62: 2192-205.
36. Billiau A, Matthys P, (2001) Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 70: 849-60.
37. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL, (2008) Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 67: 1505-15.
38. Jorgensen C, Sany J, (1994) Modulation of the immune response by the neuroendocrine axis in rheumatoid arthritis. Clin Exp Rheumatol. 12: 435-41.
39. Ribeiro-da-Silva A, Hökfelt T, (2000) Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 34: 256-271.
40. Keeble JE, Brain SD, (2004) A role for substance P in arthritis? Neurosci Lett. 6: 176-9.
41. Weidler C, Holzer C, Harbuz M, Hofbauer R, Angele P, et al. (2005) Low density of sympathetic nerve fibres and increased density of brain derived neurotrophic factor positive cells in RA synovium. Ann Rheum Dis. 64: 13-20.
42. Tran AH, Berger A, Wu GE, Paige CJ, (2009) Regulatory mechanisms in the differential expression of Hemokinin-1. Neuropeptides. 43: 1-12.
43. Cunin P, Caillon A, Corvaisier M, Garo E, Scotet M, et al. (2011) The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1β, IL-23, and TNF-like 1A expression by monocytes. J Immunol. 186: 4175-82.
44. Kurtz MM, Wang R, Clements MK, Cascieri MA, Austin CP, et al. (2002) Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene. 296: 205-12.
45. Naono-Nakayama R, Sunakawa N, Ikeda T, Nishimori T, (2010) Differential effects of substance P or hemokinin-1 on transient receptor potential channels, TRPV1, TRPA1 and TRPM8, in the rat. Subcutaneous injection of endokinin C/D attenuates carrageenan-induced inflammation. Neuropeptides. 44: 57-61.
46. Liu L, Markus I, Saghire HE, Perera DS, King DW, et al. (2011) Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil. 23: 475-83.
47. Chen DR, Cohen PL, (2012) Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumtol. 2: 159-166.
48. Popa C, Leandro MJ, Cambridge G, Edwards JC, (2007) Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 4: 626-30.
49. Krause JE, DiMaggio DA, McCarson KE, (1995) Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Can J Physiol Pharmacol. 73: 854-9.
50. Hong SK, Han JS, Min SS, Hwang JM, Kim YI, et al. (2002) Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett. 322: 21-4.
51. Lam FF, Ng ES, (2010) Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol. 159: 958-69.
52. Uematsu T, Sakai A, Ito H, Suzuki H, (2011) Intra-articular administration of tachykinin NK1 receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. Eur J Pharmacol. 668: 163-8.
53. Tauer U, Zhao Y, Hunt SP, Culman J, (2012) Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors? Neuropharmacology. 63: 958-65.
54. Lavagno L, Bordin G, Colangelo D, Viano I, Brunelleschi S, (2001) Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A. Neuropeptides. 35: 92-9.
55. Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, et al. (2011) Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol. 21: 244-50.
56. Gonzalez-Rey E, Chorny A, Delgado M, (2007) Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol. 7: 52-63.